These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 25769882)

  • 1. Re-expression of LKB1 in LKB1-mutant EKVX cells leads to resistance to paclitaxel through the up-regulation of MDR1 expression.
    Mao K; Liu F; Liu X; Khuri FR; Marcus AI; Li M; Zhou W
    Lung Cancer; 2015 May; 88(2):131-8. PubMed ID: 25769882
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modulation of MDR1 and MRP3 gene expression in lung cancer cells after paclitaxel and carboplatin exposure.
    Melguizo C; Prados J; Luque R; Ortiz R; Caba O; Alvarez PJ; Gonzalez B; Aranega A
    Int J Mol Sci; 2012 Dec; 13(12):16624-35. PubMed ID: 23443122
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NEAT1 mediates paclitaxel-resistance of non-small cell of lung cancer through activation of Akt/mTOR signalling pathway.
    Li B; Gu W; Zhu X
    J Drug Target; 2019 Dec; 27(10):1061-1067. PubMed ID: 30782035
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The tumor suppressor gene TUSC2 (FUS1) sensitizes NSCLC to the AKT inhibitor MK2206 in LKB1-dependent manner.
    Meng J; Majidi M; Fang B; Ji L; Bekele BN; Minna JD; Roth JA
    PLoS One; 2013; 8(10):e77067. PubMed ID: 24146957
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sulforaphane metabolites reduce resistance to paclitaxel via microtubule disruption.
    Wang Y; Zhou Y; Zheng Z; Li J; Yan Y; Wu W
    Cell Death Dis; 2018 Nov; 9(11):1134. PubMed ID: 30429459
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metformin and tenovin-6 synergistically induces apoptosis through LKB1-independent SIRT1 down-regulation in non-small cell lung cancer cells.
    Lee BB; Kim Y; Kim D; Cho EY; Han J; Kim HK; Shim YM; Kim DH
    J Cell Mol Med; 2019 Apr; 23(4):2872-2889. PubMed ID: 30710424
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FNDC5 promotes paclitaxel sensitivity of non-small cell lung cancers via inhibiting MDR1.
    Fan GH; Zhu TY; Huang J
    Cell Signal; 2020 Aug; 72():109665. PubMed ID: 32353410
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Calpain-2 Enhances Non-Small Cell Lung Cancer Progression and Chemoresistance to Paclitaxel via EGFR-pAKT Pathway.
    Xu F; Gu J; Lu C; Mao W; Wang L; Zhu Q; Liu Z; Chu Y; Liu R; Ge D
    Int J Biol Sci; 2019; 15(1):127-137. PubMed ID: 30662353
    [TBL] [Abstract][Full Text] [Related]  

  • 9. siRNA silencing EZH2 reverses cisplatin-resistance of human non-small cell lung and gastric cancer cells.
    Zhou W; Wang J; Man WY; Zhang QW; Xu WG
    Asian Pac J Cancer Prev; 2015; 16(6):2425-30. PubMed ID: 25824776
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug resistance to paclitaxel is not only associated with ABCB1 mRNA expression but also with drug accumulation in intracellular compartments in human lung cancer cell lines.
    Shimomura M; Yaoi T; Itoh K; Kato D; Terauchi K; Shimada J; Fushiki S
    Int J Oncol; 2012 Apr; 40(4):995-1004. PubMed ID: 22179563
    [TBL] [Abstract][Full Text] [Related]  

  • 11. LKB1 gene inactivation does not sensitize non-small cell lung cancer cells to mTOR inhibitors in vitro.
    Xiao P; Sun LL; Wang J; Han RL; Ma Q; Zhong DS
    Acta Pharmacol Sin; 2015 Sep; 36(9):1107-12. PubMed ID: 26027660
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting glucosylceramide synthase induction of cell surface globotriaosylceramide (Gb3) in acquired cisplatin-resistance of lung cancer and malignant pleural mesothelioma cells.
    Tyler A; Johansson A; Karlsson T; Gudey SK; Brännström T; Grankvist K; Behnam-Motlagh P
    Exp Cell Res; 2015 Aug; 336(1):23-32. PubMed ID: 26004871
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Effect of LKB1 Activity on the Sensitivity to PI3K/mTOR Inhibition in Non-Small Cell Lung Cancer.
    Shukuya T; Yamada T; Koenig MJ; Xu J; Okimoto T; Li F; Amann JM; Carbone DP
    J Thorac Oncol; 2019 Jun; 14(6):1061-1076. PubMed ID: 30825612
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phosphatidylinositol ether lipid analogues induce AMP-activated protein kinase-dependent death in LKB1-mutant non small cell lung cancer cells.
    Memmott RM; Gills JJ; Hollingshead M; Powers MC; Chen Z; Kemp B; Kozikowski A; Dennis PA
    Cancer Res; 2008 Jan; 68(2):580-8. PubMed ID: 18199555
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CHD1L contributes to cisplatin resistance by upregulating the ABCB1-NF-κB axis in human non-small-cell lung cancer.
    Li Y; He LR; Gao Y; Zhou NN; Liu Y; Zhou XK; Liu JF; Guan XY; Ma NF; Xie D
    Cell Death Dis; 2019 Feb; 10(2):99. PubMed ID: 30718500
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Novel Triazolonaphthalimide Derivative LSS-11 Synergizes the Anti-Proliferative Effect of Paclitaxel via STAT3-Dependent MDR1 and MRP1 Downregulation in Chemoresistant Lung Cancer Cells.
    Ji L; Liu X; Zhang S; Tang S; Yang S; Li S; Qi X; Yu S; Lu L; Meng X; Liu Z
    Molecules; 2017 Oct; 22(11):. PubMed ID: 29072615
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of ABCB1 (MDR1) and ABCB4 (MDR3) expression by small interfering RNA and reversal of paclitaxel resistance in human ovarian cancer cells.
    Duan Z; Brakora KA; Seiden MV
    Mol Cancer Ther; 2004 Jul; 3(7):833-8. PubMed ID: 15252144
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutant LKB1 Confers Enhanced Radiosensitization in Combination with Trametinib in KRAS-Mutant Non-Small Cell Lung Cancer.
    Wang Y; Li N; Jiang W; Deng W; Ye R; Xu C; Qiao Y; Sharma A; Zhang M; Hung MC; Lin SH
    Clin Cancer Res; 2018 Nov; 24(22):5744-5756. PubMed ID: 30068711
    [No Abstract]   [Full Text] [Related]  

  • 19. Molecular changes to HeLa cells on continuous exposure to cisplatin or paclitaxel.
    Takara K; Obata Y; Yoshikawa E; Kitada N; Sakaeda T; Ohnishi N; Yokoyama T
    Cancer Chemother Pharmacol; 2006 Dec; 58(6):785-93. PubMed ID: 16534613
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Variable apoptotic response of NSCLC cells to inhibition of the MEK/ERK pathway by small molecules or dominant negative mutants.
    Brognard J; Dennis PA
    Cell Death Differ; 2002 Sep; 9(9):893-904. PubMed ID: 12181740
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.